TY - JOUR AU - Brechka, N. М. AU - Kozar, V. V. AU - Bondarenko, V. O. AU - Morozenko, D. V. AU - Korenyeva, Ye. M. AU - Leontieva, F. S. PY - 2020/03/03 Y2 - 2024/03/28 TI - THE INFLAMMATORY PROCESS CORRECTION IN RATS WITH BENIGN PROSTATIC HYPERPLASIA JF - Problems of Endocrine Pathology JA - PEP VL - 71 IS - 1 SE - DO - 10.21856/j-PEP.2020.1.13 UR - https://www.jpep.endocrinology.org.ua/index.php/1/article/view/134 SP - 98-104 AB - <p>Benign prostatic hyperplasia (BPH) is a common disease which affects 50-80% of the male population<br>in old age. Based on the important role of chronic inflammation in the pathogenesis of BPH the concept of<br>its pharmacological treatment has also changed and an important property of drugs is the presence of antiinflammatory<br>effects. The purpose of the work was to evaluate the effect of Chondroitin sulfate, Bioglobin-U<br>and Tribestan on inflammation in experimental benign prostatic hyperplasia and in comparison with the<br>effects of other prostatoprotectors. BPH was caused by intraperitoneal administration of sulpiride (Eglonil)<br>at a dose of 40 mg/kg of animal body weight during 30 days. The model represents the development of lateral<br>parts hyperplasia of the prostate, which correlates with similar pathological changes in the human prostate.<br>After rats' BPH were given Chondroitin sulphate at a dose of 60 mg/kg, Chondroitin sulphate in combination<br>with Tribestan at a dose of 60 mg /kg, Tribestan (manufactured by Sopharma, Bulgaria) at a dose of 60 mg/kg,<br>and Bioglobin-U (a proteinised water-salt extract from a human placenta including polypeptides 3.5–7 %, amino<br>acids 50–60 %, amino sugars 4–5 %, hexuronic acids 8–9 %, produced by CJSC Biolik, Kharkiv) at a dose<br>of 200 μl/kg. The comparison drug was Prostaplant forte produced by Schwabe company, Germany. The drugs<br>were administered from the 30th to the 51st day of the experiment after completion of BPH modeling. The level<br>of C-reactive protein (CRP), sedimentation rate of erythrocytes (SRE), and white blood cell count have been<br>studied. It is proved that the model of prostatic hyperplasia is characterized by an increase in the number of<br>leukocytes and SRE and CRP concentration and the degree of their growth can be attributed to manifestations<br>of chronic inflammation. The studied drugs showed pronounced anti-inflammatory properties and this is<br>confirmed by a decrease of leukocytes number and SRE and the concentration of CRP in rats with experimental<br>benign prostatic hyperplasia. According to the results of a study of Сhondroitin sulfate, Bioglobin-U had<br>more pronounced antiinflammatory properties. Chondroitin sulfate reduced SRE more effectively than the<br>comparison drug Prostaplant forte. The studied preparations of Сhondroitin sulfate and Bioglobin-U which have<br>pronounced anti-inflammatory properties can be recommended for use in benign prostatic hyperplasia to reduce<br>the manifestations of inflammation.</p> ER -